Here we are looking at Intendis (part of the Bayer Group) and Coria Laboratories who are promoting Finacea Plus; the combination of Finacea and 3 oz bottles of CeraVe Moisturizing Lotion and CeraVe Hydrating Cleanser.

The promotional offer is a Finacea + CeraVe Coupon that will save you $10 off Finacea and $2 off the CeraVe Moisturizer or Cleanser. Not much of a discount, but as you can see it is enough to build a colourful advertising campaign.

Finacea Plus is “For the multi-faceted challenges of mild to moderate rosacea” and is claimed to be “Offering more in one convenient package”. The coupon itself is available at the My Finacea web site.

(click to view larger image)

I wonder if offering a package of products with a glossy campaign is persuasive enough to link Finacea and CeraVe in peoples’ minds ? Do you feel a subconscious link building between the two ?

What next – should Galderma consider offering Metrogel with a couple of Cetaphil products ? Makes sense to me.

Featured Products

CeraVe Hydrating Cleanser (12 oz), CeraVe Moisturizing Lotion (12 oz)

Related Articles

• CeraVe Hydrating Cleanser and CeraVe Moisturizing Lotion User Reviews
• Finacea User Reviews

Here are example screen shots of what the introductory and red and blue screens look like when running the Acne Application.

AcneApp also scored a brief mention last December in the New York Times article Better Skin to the Touch? The piece offers the opinion from its creator that a lot more clinical study is required before any efficacy can be quantified. Dr. Pearson is said to fascinated by the concept of users treating their acne while talking on the phone.

An iPhone application is a small program that you can download and run on your phone.

According to a piece in WebMD, Dr. Pearson was not available to comment on the application, nor is his office able to comment on or support users of the application.

This application is no doubt only garnering publicity because it is not a free application. If the application was free it could easily be characterised as only being for entertainment value. Once an application costs money and looks like it treats a medical condition, it is natural for readers’ interests to be piqued.

So what is going on here ? The use of LED therapy to treat skin conditions is a hot topic. Various studies have shown that red and blue LEDs can offer anti-inflammatory benefits to some of the symptoms of acne and rosacea. The display on the iPhone is a LED display. The makers of this phone application want us to make the leap of faith that because the iPhone can display colors that are thought to be helpful, LED therapy is literally just a phone call away.

Dr. Pariser, president of the AAD says that the output from the iPhone would need to increase a thousands times to match treatments available from professional LED treatments.

Can You Treat Acne With an iPhone App?

AcneApp Promises to Clear Skin With Light Therapy; Dermatologists Express Doubts

By Kathleen Doheny, WebMD Health News. Reviewed By Louise Chang, MD

Feb. 12, 2010 — iPhone users love their apps, so it’s no surprise that AcneApp, a light-based therapy, is drawing interest from the blemish-prone who like the concept of zapping zits while talking to friends.

It’s supposed to work like this: Download the application and hold the phone to the skin so the light therapy can do its work. Multitask if you wish, remembering to switch sides so your entire face gets the treatment.

But more than four months after its release, there are still no clinical studies proving it works. Other dermatologists express doubt it could help, and users are giving it mixed reviews — from terrific to skeptical.

…

Though the wavelength of light used in the AcneApp is similar to that used in office-based light treatments, the intensity of the light used by dermatologists "is at least thousands of times greater," agrees David Pariser, MD, a Norfolk, Va., dermatologist and president of the American Academy of Dermatology. "I would be very surprised if there is enough intensity of the light [from AcneApp] to make any difference."

…

So aside from wasting $1.99 and still coping with zits, is there any potential harm?

Yes, Rahimi says. "I am worried about the patient with deep cystic acne and open, draining sores that uses this app." Bacteria on the phone could lead to a skin infection, he says.

The application is available from the iTunes Store: AcneApp, but I wouldn’t recommend it.

Related Articles

• new mixed LED therapy for acne
• LED helps recovery after IPL, reduces redness
• RLT and pore size
• LED Therapy Gaining Popularity
• Red LED Lamps & Other Forms of Low-Level Light Therapy

The program list from the recent AAD meeting in Florida gives an idea of where Galderma are concentrating their promotional efforts.

Let us start with the list of advertisers ;

You can see that Galderma is far and away the most prominent advertiser.

Many won’t have seen these advertisements, so here we are, a snapshot of the sorts of marketing material that Galderma is using to target practitioners. In the handouts each prescription product is normally accompanied by a second page comprising the mandatory prescribing information.

Click on the images for a bigger version.

Oracea

Oracea is promoted as a `direction’ that is a `Power Change for the Journey Ahead’. The advertisement is highlighting the low incidence of side effects, a similar efficacy to 100mg doxycycline and a reduction in lesions in as little as 4 weeks. Using words like journey and `better tomorrow’ and mentioning that no side effects were seen in 9 months suggests that Oracea is seen as a long term prescription.

Oracea has been earned marketing awards in the past. In September 2009 we learnt that Oracea is worth $104m a year.

Metrogel 1%

Tagline: In the world of rosacea sufferers, it all comes back to the one.

When the patent on Metrogel expired, other companies have been free to market their own generic metronidazole. Galderma then launched a modified version of metrogel, increasing the concentration of metronidazole from 0.75% to 1%. The formulation was `enhanced with HSA-3 and niacinamide. HSA-3 is described as a combination of ingredients including betadex, niacinamide (vitamin B3), and propylene glycol.”

Cetaphil

Tagline: Essential for a balanced diet for healthy skin. and Every Body Benefits.

Galderma here are promoting what it sees as a non-irritating cleanser, fragrance-free moisturizer, being non-greasy and non-comedogenic and being ideal for face, hands and body.

Sponsorships

Galderma is one of the major sponsors of the National Rosacea Society. You can see from the  NRS web site, Galderma’s donations enable the NRS to conduct their educational program.

Other Products

Of course Galderma is also developing a product dubbed sansrosa, it calls CD07805/47. If and when this product comes to market, Galderma’s rosacea portfolio will be even more impressive.

So What ?

OK so this is all interesting, but what would you like to see from Galderma ? How would you like to see the deepest pockets in the industry spend their research, development and promotional dollars ?

Related Articles

• L’Oréal strong sales via Galderma and dermatology
• Galderma suing Mylan Pharmaceuticals over Oracea
• Cetaphil gentle skin cleanser well tolerated
• Metronidazole (metrogel, flagyl) popular rosacea treatment
• Oracea to replace Periostat, new rosacea treatment launched

I have to admit that I hate shaving. It seems such a waste of time to me. Every morning I need to devote 10-15 minutes to scrape the dead wire-like hair off my face. Not only is it messy, but it hurts. I have tried an electric razor but it just doesn’t cut it. Only in recent years have I been able to shave with a blade razor. My facial skin has been too sensitive to cope with a razor blade. Any small cuts would turn into a pustule. Any small papule was in danger of being sliced open. The irritation from shaving certainly didn’t enhance the redness of my rosacea.

I have seen shaving oils talked about in the past. Surely they don’t work though right ? The best way to shave is to have a heap of creamy lather ? Well now I’m not sure. In fact I’m almost ready to discard shaving cream for good.

For the last 2 weeks I have been using Dermalogica Close Shave Oil. For the first time in as long as I can remember, I no longer cut myself during my early morning facial scraping. Not only do I emerge from the bathroom without several nicks (suggesting that I don’t know how to shave) I also have the closest and smoothest shave I can remember.

As the oil is clear and you apply so little, you can see exactly where you are shaving. Until you get used it actually working you won’t believe that something you can’t see actually does a good job.

The slight smell reminds me a bit of camphor oil, it is a little bit of an unusual smell, certainly not the perfume I used to.

The instructions say to shake a few drops into a wet palm and smooth over dampened area to be shaved. Rinse razor often. This last tip is important as the oil tends to cause the razor to become blocked with the accumulation of the stubble. If you don’t rinse often and vigorously, you will certainly clog the razor solid.

Afterwards I find that my usual cleanser – Cetaphil Gentle Skin Cleanser doesn’t give a great feeling of washing off the oil. I moisturize anyway with Cetaphil Moisturizer and so far I haven’t noticed any bad reaction from the oil.

The price may seem a little steep for a small bottle, but 4 drops is enough for a strong beard. I expect my bottle to last several months at least. The oil is perfect for travelling, the bottle is so much smaller and lighter than a can of shaving foam.

Hey one last tip – it is great for shaving your legs too.

Official Product Description

“This slick oil is perfect for shaving goatees, moustaches and sideburns, or for those who prefer maximum visibility while shaving. Formulated with a rich blend of botanicals, Close Shave Oil comforts and soothes the skin while lifting the hairs for an irritation-free finish. Silicones allow the razor to glide evenly over the skin to minimize the risk of nicks, cuts and razor burn. Camphor diminishes irritation while thyme, clove, lavender and tea tree condition and soften the skin. Free of artificial colorants and fragrances, and suitable for shaving the head.”

Ingredients

The first ingredients give a clue to why to works so well – lubricants that help the razor smooth across the skin.

Dimethicone, Cyclomethicone, Amodimethicone, Dimethiconol, Melaleuca Alternifolia (Tea Tree) Leaf Oil, Lavandula Angustifolia (Lavender) Oil, Citris Aurantium Dulcis (Orange) Oil, Ocimum Basililicum (Basil) Oil, Cananga Odorata (Ylang-Ylang) Flower Oil, Pinus Palustris (Pine) Oil, Thymus Vulgaris (Thyme) Oil, Eugenia Carypophyllus (Clove) Flower Oil, Pogostemon Cablin Oil, Cedrus Atlantica (Cedarwood) Bark Oil, Melaleuca Leucadendron Cajaput Oil, Glycine Soja (Soybean) Oil, Camphor, Limonene, Linalool.

Final Remarks

OK, I don’t think I have raved about a product in this way for a long time. It is nice to find a product that you really like, one that works as it is advertised. I think this oil will remain in my box of toiletries.

If you find shaving is causing you irritation, please let us know if this product helps you.

Featured Product

Dermalogica Close Shave Oil

Related Articles.

• `shaving’ via light lamp promises low irritation
• Dermalogica: close shave oil

Microskin mention rosacea as one of the conditions that they treat. The product is slated as a simulated second skin. The product is applied using a Stipple (a special type of sponge) or an air brush for larger areas.

The company says that the product will not rub off, is completely waterproof, allows the skin to breathe and sweat, and lasts for several days.

The New York Times published an article on February 24, 2010 that highlighted the use of microskin as a coverup for Vitiligo.

Vitiligo: Ignoring What Is Painfully Obvious

Starting on Friday, vitiligo patients will have an alternative stateside. Microskin — a simulated second skin that’s been available in Australia for years — is set to open its first outpost in the United States at the Laser and Skin Surgery Center of New York, in Midtown. Microskin is formulated to bridge the gap between a vitiligo patient’s paler patches and unaffected skin so that skin tone appears even. (It can also cover burns, birthmarks and the effects of psoriasis.)

Each shade is customized. “There’s only one skin color for one person in the world,” said Linda Lowndes, who founded Microskin in 2005 after working as a makeup artist. “I don’t care if you’re black or white.”

Microskin is waterproof and won’t rub off on clothing. “You’ve got to use a removing serum to break the barrier,” she said, referring to a liquid that is included in the Microskin system.

…

Still, at the start, applying Microskin on his face, arms and legs would take 75 minutes, which was “pretty annoying,” he said. He does his face daily, but Microskin lasts for a few days elsewhere. And practice has made the application faster.

The Microskin system, with training, starts at $670 for sponge application and rises to $2,250 for airbrush application. Seasonal scans ($200) are recommended to update your Microskin shade.

The article also mentions Dermablend, ColorTration and Cover FX as options for covering up

Another option is camouflage. Some patients with vitiligo, rosacea or birthmarks rely on opaque foundations specially marketed to mask them. Dermablend and ColorTration are two. Lee Thomas, a television broadcaster who wrote a book about his vitiligo called “Turning White,” endorses another foundation, Cover FX, on his Web site.

For more information about Microskin see:

US Site: http://www.microskincenter.com/

Australian site: http://www.microskin.com.au/

Microskin has been in contact with me in the past and say that they have seen rosacea patients. Microskin received national coverage in a 2006 item on A Current Affair titled Second Skin (the video link to the article doesn’t appear to work).

There are very few good treatments for the redness of rosacea. Being able to cover the red angry face of rosacea can do wonders for self esteem.

Would love to hear from anyone who tries it to cover up their rosacea.

Related Articles

• facial blemishes: makeup is not enough
• Makeup & Cover Up Forum
• A guide to Makeup and Cover Up Brushes
• tinted moisturizers, ever tried them ?
• what is the best moisturizer for rosacea ?

A recent article from ABC7 featuring a skin analysis tool called VISIA Complexion Analysis System. The article suggests that the system uses multiple measures, including a porphyrin count to predict how likely a person is to get acne or rosacea. The system also gives a measure of the `skin age’ of an individual.

The VISIA Complexion Analysis web site lists the six key factors assessed as

• wrinkle
• spots
• pore size
• skin tone variations
• bacterial content
• UV spots that indicate sun damage

It would be interesting to see whether there is any research available linking the prevalence of porphyrin and the incidence of rosacea. It might be possible that sun damage is linked to rosacea in some individuals so this tool could have some use. It is a nice idea to be able to predict if someone is likely to develop rosacea, but I do have to wonder if such a tool could be as simple as the one featured here.

As a related noted, a rare but painful disease  known as Erythropoietic Protoporphyria (EPP) is caused by a build up of protoporphyrin in the skin. Exposure to the sun causes these molecules to be phototoxic.

The VISIA skin analysis consultation is free, with doctors hoping to offer you treatments like dermal fillers or laser treatments to reduce the visible signs of skin ageing.

The related video ends with advice to cover up outside, wear sunscreen etc. This is good advice even if you aren’t worried about your apparent skin age getting ahead of your real age.

New system shows your skin’s true age

Monday, March 01, 2010

BEVERLY HILLS, Calif. (KABC) — With every birthday, you become all too aware of your chronological age. But your skin age might have a different number. Is your skin aging prematurely? Take a look at a machine that helps doctors predict what the future holds for your face.

…

"This type of machine shows us a lot more detailed specifications of aging," said Dr. Ourian. "I can find out if a person’s pores are getting to be too large, which actually shows me if their skin is losing its elasticity."

It’s called the VISIA Complexion Analysis System, and it sees the beginnings of fine wrinkles, UV-ray damage and discoloration. It takes a porphyrin count to predict how likely a person is to get acne or rosacea.

Related Articles

• Suffering as bad as it gets; Erythropoietic Protoporphyria
• Phototherapy: a guide to the pitfalls of terminology
• rosacea, red light (acne lamp), clonidine and noritate

The Clinical Research Unit is seeking men and women, at least 18 years old, to participate in a research study of a new oral investigational treatment for Rosacea.

The study requires 10 visits over 16 weeks.

Participants may be eligible to receive:

• Free facial skin examinations
• Free medication
• Compensation of up to $250

Contact:

• Department of Dermatology Clinical Research Unit
• Telephone:  212-305-6953

Email:  cc2241@columbia.edu

The CEO and Director of Clinuvel, Dr Philippe Wolgen, was kind enough to answer some questions relating to their developments and any potential tie-in with rosacea. Thanks Dr. Wolgen for taking the time to help us understand what Clinuvel is up to and how that fits in with what we can find on the internet.

1. We have heard of Melanotan, what is that?

In the early eighties, ‘Melanotan’ was a trade name for a series of peptides developed as potential skin cancer preventatives at the University of Arizona. These names are no longer used by the University and related companies.

In more recent times, the term ‘Melanotan’ has been associated and used by online vendors selling illegal chemicals over the net, whereby these pirates falsely claim that they are selling clean hormonal drugs. These chemicals have never been tested, have not received regulatory approval anywhere in the world and are a health hazard to consumers buying them online. Most of these consumers believe that these chemicals are safe tanning alternatives.

On the other hand, pharmaceutical drugs developed under controlled conditions and which receive regulatory approval for testing are subject to strict regulations, including controls on how they are manufactured, their purity levels and ingredients, their methods of administration and close monitoring by medical experts. Chemicals sold online as ‘Melanotan’ undergo none of these tests, and the public is warned to refrain from these substances.

2. How about afamelanotide, where does that fit in?

Afamelanotide is an optimized synthetic peptide manufactured under supervision of a global manufacturer, which is authorized by the FDA and EMA to synthesize legitimate amino acids to peptides.

Clinuvel has the exclusive worldwide rights to develop afamelanotide and it has chosen to develop the drug as the world’s first ‘medicinal photoprotective’ – that is, a drug that provides endogenous (from within) skin protection from UV and light.

Clinuvel has refined this drug since its early development; refining both the active pharmaceutical ingredient’s method of manufacture and ingredients, as well creating a novel delivery system: a controlled-release dissolvable implant. The drug is now administered by physicians as a subcutaneous implant – roughly the size of a grain of rice – which disappears after days. The effect of the drug lasts two months.

We’ve identified the most severe UV and -light related skin disorders and have tested afamelanotide for the past 10 years in humans to measure its photoprotective effect. Not only have we seen clinical response in these patients, more important is that we have seen a very safe profile in afamelanotide.

EPP is the lead indication, meaning where this drug is first used, and, we believe, the one for which patients have the greatest need for medicinal photoprotection.

3. There might be confusion surrounding some of the terminology people find on the internet. Please could you tell help us distinguish Epitan, Melanotan, Melanotan 2 and Afamelanotide?

Afamelanotide is the generic name of Clinuvel’s molecule and is not related to the chemicals sold today as ‘Melanotan’. Afamelanotide is a legitimate pharmaceutical ingredient being developed into a therapeutic product with a safe track record.

‘Melanotan’ and ‘Melanotan 2’ are self-injectable or inhalable chemicals and their names have been used by unscrupulous vendors online to sell chemicals of unknown origin purporting to have a cosmetic tanning effect or causing weightloss and libido enhancing. These are not pharmaceutical products: their manufacture, ingredients and use are unknown and their potential effects are unknown.

Nowhere in the world are products being sold online as ‘Melanotan’ or ‘Melanotan 2’ being tested in legitimate clinical trials; unfortunately those selling these chemicals are linking legitimate scientific research to their products in an attempt to legitimize their operations.

Epitan is a company that is no longer in existence.

4. Products seem to take years and years to become available. When might afamelanotide be available to doctors?

The approval and sale of drugs is regulated in every country or territory by a different regulatory agency (such as the FDA in the USA, EMA in Europe or TGA in Australia). Regulators review the history and development of a drug in depth once a final dossier of data is submitted by a sponsor company. The key regulatory review is whether a drug is safe and well tolerated by the patients for whom it is intended. Regulators then review the data to determine whether a drug is effective in preventing or treating the patients for whom it is intended and whether a drug is safe for human use. A drug is approved when a regulatory agency completes a review of the data presented by the sponsor and agrees that the effect of the drug in patients outweighs the possible risks or side effects posed by that drug. The process up until the regulatory review can take many years; the average time for a drug to reach the market from the lab is 10 years. Companies may spend an average of $US1billion getting drugs to market and, sadly, the vast majority of drugs fail well before they reach the market. It’s estimated that about one in every 10,000 molecules discovered in the lab will reach the market as a pharmaceutical product. Of every three drugs to reach Phase III (the last stage of clinical development), roughly two will fail.

Clinuvel is nearing the completion of its development program after more than a decade, and it is in this context that Clinuvel is developing a first-in-class drug, afamelanotide. We have taken a cautious and conservative approach by generating data preclinically and clinically, perhaps more than is strictly necessary to evaluate the safety of afamelanotide.

We are due to release full results from our first ever completed Phase III study before the end of March. Pending the results of this trial, we will make the decision of when to file a dossier for Marketing Authorisation with regulators. This will happen with European regulators first (a central procedure through the European Medicines Agency), followed by Switzerland, Australia and then the US. The timing is then dependant upon the regulatory process, which can take anywhere from 3-9 months. We’re posting overviews and discussion related to pharmaceutical development on our blog.

5. What are your thoughts about off-label usage of prescription products?

I have published my thoughts in an exploration of the subject of off-label use on the Clinuvel blog.

As a physician, I think off-label use is risky as most drugs have been tested in one disease only. The decision to prescribe the same drug for other diseases is often not founded on the testing data. A physician has certain autonomy, but the health of his patients should dominate his or her decisions. In this sense I am risk averse and conservative.

6. There are a number of individuals with rosacea who believe that afamelanotide may be an appropriate treatment for them; have you ever trialled the drug in rosacea?

We have not trialled afamelanotide in rosacea, so the drug’s effects are unknown.

7. Is there a possibility that afamelanotide may be effective in rosacea?

Unless a trial is conducted, it is impossible to speculate on the drug’s effects.

It is important to note, however, that a drug’s effects will vary from patient group to patient group; it is not wise to assume that what works in one indication will necessarily work in another.

8. Do you think your company might maintain an interest in the future with respect to rosacea?

For the moment we are focused on our chosen regulatory program

While we welcome the interest generated by individuals with rosacea, at present we are focused on completing our program in the other diseases.

9. Various `melanin enhancers’ (for want of a better term) seem to be available on the internet. What advice would you offer to those who are desperate or are interested in experimenting?

Consumers should note that there are currently NO prescriptive or pharmaceutically approved drugs to enhance pigmentation. Individuals should not use any product which has not been prescribed by a physician.

The internet phenomenon is a new challenge for the pharmaceutical industry, with consumers becoming gate keepers, but people need to be aware of the risks that these products can pose to their health.

10. Thanks for doing this Q&A, where can I find more information about Clinuvel?

The website at www.clinuvel.com is the best way to keep in touch with the company’s updates. We also maintain a twitter feed @ClinuvelNews and support a group on Facebook, the Photoprotection Network.

Clinuvel also maintains an extensive resource library online on UV, light, skin and melanin which may be of interest to your readers.

Finally, as part of our ongoing commitment to quality online information, many of these networks will be upgraded in the coming months to help people better understand what the company does and the industry in which we work.

Thanks Dr. Wolgen, we are grateful for your time and expertise.

Related Articles

• Photoprotection expertise from Clinuvel
• Afamelanotide (Clinuvel CUV1647) gets orphan drug status in the US
• Afamelanotide continues promising results
• Suffering as bad as it gets; Erythropoietic Protoporphyria

Dr. Nielson became known to rosacea sufferers via the way that his Rosacea Institute of Texas was heavily promoted by Geoffrey Nase. The results being promised and the treatment protocols proposed raised the suspicion of some rosacea sufferers. Now, a few years later we can all see that the partnership between Nielson and Nase was indeed based on unsustainable promises and poor medicine.

Medical Board Disciplines 70 Doctors and Issues 671 Licenses

FOR IMMEDIATE RELEASE
Wednesday, February 17, 2010

Nielson, David Hugh, M.D., Lic. #K0962, San Antonio TX

On February 5, 2010, the Board and Dr. Nielson entered into an agreed order requiring Dr. Nielson to complete 15 hours of CME in medical record-keeping, risk management and ethics within one year; and pay an administrative penalty of $4,000 within 60 days.

The action was based on the Board’s finding that Dr. Nielson

• failed to keep adequate medical records
• failed to use proper diligence in his professional practice, and
• failed to adequately supervise the activities of those acting under his supervision.

The Board found that digital photos that were part of patient records were inadvertently deleted and that Dr. Nielson authorized a person to represent his clinic and that person misrepresented risks and procedures for Dr. Nielson’s treatment of rosacea.

The full disciplinary notice is available publicly and offers further statements detailing the reason that Nielson has been ordered to pay a penalty and undertake extra education. More specifically the medical board made the following findings with respect to the partnership between Nielson and Nase.

• Nase was heavily involved in treatment plans, even though not present, with the care and treatment of patients at the Rosacea Treatment Institute of Texas.
• Nase conducted telephoned and email consultations, on Nielson’s behalf and under Nielson’s authority.
• Nase misrepresented risks and procedures for the treatment of rosacea generally, comparative risks related to Nielson’s treatments, the professional superiority of Nielson’s treatment procedures and optimistic outcome of Nielson’s treatments citing minimal side effects, long-lasting improvement and in some cases, even permanent improvement.

I think the rosacea community is well within its rights to feel especially aggrieved about this last finding. Rosacea sufferers, especially those desperate for relief deserve better than being preyed on by unscrupulous practitioners.

This order comes just a few days after we learned that Dr. Syed had been charged for posing as a doctor.

I wish I could offer better advice than the obvious statement that if something sounds too good to be true then it probably is.

Be careful out there.

Related Articles

• Dr. Syed charged for posing as a doctor
• Rosacea Guru to end battle over critic’s site
• Debunking Dr. Geoffrey Nase

According to Albert M. Kligman, 93, dermatology researcher, Dr. Kligman cowrote 14 books, beginning with Textbook on Dermatology, published by W.B. Saunders in Philadelphia in 1956, and ending with the third edition of Acne and Rosacea, published by Springer Verlag in Berlin in 2000.

Dr. Kligman passed away on Feb 9, 2010 aged 93.

Kligman’s 2004 Critique on the state of Knowledge of Rosacea was scathing about the poor State of the Art of Rosacea Research and Development.

This quote was quite insightful: “It seems that rosacea is a physician-friendly disorder in which everything works. This brings to mind the old clinical adage that when everything works, nothing works! Of course, we all understand how it happens that industry supported research is unlikely to yield negative results” and further “I hold that studies of papulo-pustular rosacea has brought in the marketplace too many drugs of marginal efficacy making it almost impossible for clinicians to make rational choices among the offerings, especially when these are backed up by heavy investments in marketing”

Kligman is credited in the Standard grading system for rosacea, the Standard classification of rosacea as well as the Standard Management Options for rosacea.

In his recently published book, Rosacea: Diagnosis and Management, Dr. Powell tells us that the 1993 book Acne & Rosacea by Plewig & Kligman is still the preferred authorative medical reference for rosacea. This is a bit of a shame because this book is out of print. You may be able to find a copy in your library, or you can also sometimes purchase a second hand copy via Amazon.com.

The good news is that an updated hardcover version, Pathogenesis and Treatment of Acne and Rosacea, edited in parth by Kligman is due to be released in August 2010.

Albert M. Kilgman is considered truly as one who was larger than life. A 2006 paper in the Journal of Investigative Dermatology said of him “Albert Kligman is among many other things, a dreamer.
Through his vision and its implementation he has been a major force in directing dermatology toward a better future. His dermatologic dreams have been well realized”

Related Articles

• Kligman on the state of Rosacea Knowledge